16.12.2025
US President Donald Trump said he is considering an executive order to reclassify marijuana as a less dangerous drug – a decision that could reshape the cannabis industry, ease criminal penalties and unlock billions in research funding.
The shift would represent one of the most significant federal changes to marijuana policy in decades, reducing oversight to the level of common prescription drugs and potentially opening doors long closed to banks and investors.
“We are looking at that very strongly,” Trump told reporters in the Oval Office, responding to reports that he is looking at directing federal health and law enforcement agencies to treat marijuana as a Schedule III drug.
Do you have questions about the biggest topics and trends from around the world? Get the answers with SCMP Knowledge, our new platform of curated content with explainers, FAQs, analyses and infographics brought to you by our award-winning team.
“A lot of people want to see it – the reclassification – because it leads to tremendous amounts of research that can’t be done unless you reclassify,” he said.
Under the US Controlled Substances Act, marijuana is listed as a Schedule I substance like heroin, ecstasy and peyote, implying it has a high potential for abuse and no currently accepted medical use.
Initial reports that Trump might loosen federal restrictions on the psychoactive drug sent stocks of cannabis-related companies higher. They stand to benefit by making more cannabis products.
The shift could reshape the industry by potentially lowering taxes and making it easier to secure funding. Schedule III drugs include Tylenol mixed with codeine, ketamine and testosterone. Agency reports
